Frailty among Alzheimer’s disease patients

CNS and Neurological Disorders - Drug Targets

Volumn 12, Issue 4, 2013, Pages 507-511

  Koch, Giacomo ^a,b   Belli, Lorena ^a   Lo Giudice, Temistocle ^a   Di Lorenzo, Francesco ^a   Sancesario, Giulia Maria ^a   Sorge, Roberto ^a   Bernardini, Sergio ^a   Martorana, Alessandro ^a,b  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

Alzheimer s disease; Amyloid 42; Frailty; Mini mental state examination; Tau protein

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; C REACTIVE PROTEIN; D DIMER; FIBRINOGEN; PHOSPHOPROTEIN; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); APOLIPOPROTEIN E; PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; DISEASE COURSE; FIBRINOGEN BLOOD LEVEL; FRAILTY; HUMAN; INFLAMMATION; MINI MENTAL STATE EXAMINATION; PROTEIN BLOOD LEVEL; ANALYSIS OF VARIANCE; CEREBROSPINAL FLUID; FRAIL ELDERLY; PHOSPHORYLATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; APOLIPOPROTEINS E; DISEASE PROGRESSION; FRAIL ELDERLY; HUMANS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; TAU PROTEINS;

EID: 84894344018     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527311312040010     Document Type: Article

References (51)

1. Yates, F.E. Complexity of a human being: changes with age. Neurobiol. Aging, 2002, 23(1), 17-19.
2. Folstein, S. Functional expressions of the aging brain. Nutr. Rev., 2010, 68(Suppl 2), S70-S73.
3. Topinková, E. Aging, disability and frailty. Ann. Nutr. Metab., 2008, 52(Suppl1), 6-11.
4. Mitnitski, A.B.; Mogilner, A.J.; Rockwood, K. Accumulation of deficits as a proxy measure of aging. Sci.World J., 2001, 1, 323-336.
5. Kirkwood, T.B. Time of our lives. What controls the length of life? EMBO Rep., 2005, 6(Spec No), S4-S8.
6. Espinoza, S.; Walston, J.D. Frailty in older adults: insights and interventions. Cleve Clin. J. Med., 2005, 72(12), 1105-1112.
7. Lang, P.O.; Michel, J.P.; Zekry, D. Frailty syndrome: a transitional state in a dynamic process. Gerontology, 2009, 55(5), 539-549.
8. Rockwood, K.; Song, X.; MacKnight, C.; Bergman, H.; Hogan, D.B.; McDowell, I.; Mitnitski, A. A global clinical measure of fitness and frailty in elderly people. Can. Med. Assoc. J., 2005, 173(5), 489-495.
9. Fried, L.P.; Tangen, C.M.; Walston, J.; Newman, A.B.; Hirsch, C.; Gottdiener, J.; Seeman, T.; Tracy, R.; Kop, W.J.; Burke, G.; McBurnie, M.A.; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J. Gerontol. A Biol. Sci. Med. Sci., 2001, 56(3), M146-M156.
10. Newman, A.B.; Brach, J.S. Gender gap in longevity and disability in older persons. Epidemiol. Rev., 2001, 23(2), 343-350.
11. Lanfranco, F.; Gianotti, L.; Giordano, R.; Pellegrino, M.; Maccario, M.; Arvat, E. Ageing, growth hormone and physical performance. J. Endocrinol. Invest., 2003, 26(9), 861-872.
12. Leng, S.X.; Tian, X.; Matteini, A.; Li, H.; Hughes, J.; Jain, A.; Walston, J.D.; Fedarko, N.S. IL-6-independent association of elevated serum neopterin levels with prevalent frailty in community-dwelling older adults. Age Ageing, 2011, 40(4), 475-481.
13. Braw, Y.; Aviram, S.; Bloch, Y.; Levkovitz, Y. The effect of age on frontal lobe related cognitive functions of unmedicated depressed patients. J. Affect. Disord., 2011, 129(1-3), 342-347.
14. Semprini, R.; Lubrano, A.; Misaggi, G.; Martorana, A. Apathy as marker of frail status. J. Aging Res., 2012, 2012, 436251.
15. Walston, J.; McBurnie, M.A.; Newman, A.; Tracy, R.P.; Kop, W.J.; Hirsch, C.H.; Gottdiener, J.; Fried, L.P.; Cardiovascular Health Study. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study. Arch. Intern. Med., 2002, 162(20), 2333-2341.
16. Roubenoff, R. Catabolism of aging: is it an inflammatory process? Curr. Opin. Clin. Nutr. Metab. Care, 2003, 6(3), 295-299.
17. Buchman, A.S.; Schneider, J.A.; Leurgans, S.; Bennett, D.A. Physical frailty in older persons is associated with Alzheimer disease pathology. Neurology, 2008, 71(7), 499-504.
18. Panza, F.; Solfrizzi, V.; Frisardi, V.; Maggi, S.; Sancarlo, D.; Adante, F.; D'Onofrio, G.; Seripa, D.; Pilotto, A. Different models of frailty in predementia and dementia syndromes. J. Nutr. Health Aging, 2011, 15(8), 711-719.
19. Pilotto, A.; Rengo, F.; Marchionni, N.; Sancarlo, D.; Fontana, A.; Panza, F.; Ferrucci, L.; FIRI-SIGG Study Group. Comparing the prognostic accuracy for all-cause mortality of frailty instruments: a multicentre 1-year follow-up in hospitalized older patients. PLoS One, 2012, 7(1), e29090.
20. Depp, C.A.; Jeste, D.V. Definitions and predictors of successful aging: a comprehensive review of larger quantitative studies. Am. J. Geriatr. Psychiatry, 2006, 14(1), 6-20.
21. Knopman, D.S.; Roberts, R. Vascular risk factors: imaging and neuropathologic correlates. J. Alzheimers Dis., 2010, 20(3), 699-709.
22. Skoog, I.; Gustafson, D.: Hypertension, hypertension-clustering factors and Alzheimer's disease. Neurol. Res., 2003, 25(6), 675-680.
23. Mulder, S.D.; Hack, C.E.; van der Flier, W.M.; Scheltens, P.; Blankenstein, M.A.; Veerhuis, R. Evaluation of intrathecal serum amyloid P (SAP) and C-reactive protein (CRP)synthesis in Alzheimer's disease with the use of index values. J. Alzheimers Dis., 2010, 22(4), 1073-1079.
24. Bi, B.T.; Lin, H.B.; Cheng, Y.F.; Zhou, H.; Lin, T.; Zhang, M.Z.; Li, T.J.; Xu, J.P. Promotion of β-amyloid production by C-reactive protein and its implications in the early pathogenesis of Alzheimer's disease. Neurochem. Int., 2012, 60(3), 257-266.
25. Caselli, R.J.; Couce, M.E.; Osborne, D.; Deen, H.G.; Parisi, J.P. From slowly progressive amnesic syndrome to rapidly progressive Alzheimer disease. Alzheimer Dis. Assoc. Disord., 1998, 12(3), 251-253.
26. van der Vlies, A.E.; Verwey, N.A.; Bouwman, F.H.; Blankenstein, M.A.; Klein, M.; Scheltens, P.; van der Flier, W.M. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. Neurology, 2009, 72(12), 1056-1061.
27. Wallin, A.K.; Blennow, K.; Zetterberg, H.; Londos, E.; Minthon, L.; Hansson, O. CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology, 2010, 74, 1531-1537.
28. Schmidt, C.; Redyk, K.; Meissner, B.; Krack, L.; von Ahsen, N.; Roeber, S.; Kretzschmar, H.; Zerr, I. Clinical features of rapidly progressive Alzheimer's disease. Dement. Geriatr. Cogn. Disord., 2010, 29(4), 371-378.
29. Portet, F.; Scarmeas, N.; Cosentino, S.; Helzner, E.P.; Stern, Y.: Extrapyramidal signs before and after diagnosis of incident Alzheimer disease in a prospective population study. Arch. Neurol., 2009, 66(9), 1120-1126.
30. Martorana, A.; Esposito, Z.; Di Lorenzo, F.; Giacobbe, V.; Sancesario, G.M.; Bucchi, G.; Bonnì, S.; Bernardini, S.; Sorge, R.; Sancesario, G.; Bernardi, G.; Caltagirone, C.; Koch, G. Cerebrospinal fluid levels of Aβ42 relationship with cholinergic cortical activity in Alzheimer's disease patients. J. Neural Transm., 2012, 119(7), 771-778.
31. Martorana, A.; Di Lorenzo, F.; Esposito, Z.; Lo Giudice, T.; Bernardi, G.; Caltagirone, C.; Koch, G. Dopamine D2-agonist rotigotine effects on cortical excitability and central cholinergic transmission in Alzheimer's disease patients. Neuropharmacology, 2013, 64, 108-113.
32. Carlesimo, G.A.; Caltagirone, C.; Gainotti, G. The Mental Deterioration Battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of the Mental Deterioration Battery. Eur. Neurol., 1996, 36, 378-384.
33. Sancesario, G.M.; Esposito, Z.; Nuccetelli, M.; Bernardini, S.; Sorge, R.; Martorana, A. Detection in CSF of Alzheimer's disease is influenced by temperature: Indication of reversible Abeta1-42 aggregation? Exp. Neurol., 2010, 223(2), 371-376.
34. Martorana, A.; Sancesario, G.M.; Esposito, Z.; Nuccetelli, M.; Sorge, R.; Formosa, A.; Dinallo, V.; Bernardi, G.; Bernardini, S.; Sancesario, G. Plasmin system of Alzheimer's disease patients: CSF analysis. J. Neural Transm., 2012, 119(7), 763-769.
35. Tsukamoto, K.; Watanabe, T.; Matsushima, T.; Kinoshita, M.; Kato, H.; Hashimoto, Y.; Kurokawa, K.; Teramoto, T. Determination by PCR-RFLP of apo E genotype in a Japanese population. J. Lab. Clin. Med., 1993, 121(4), 598-602.
36. van Kan, A.G.; Rolland, Y.; Bergman, H.; Morley, J.E.; Kritchevsky, S.B.; Vellas, B. The I.A.N.A Task Force on frailty assessment of older people in clinical practice. J. Nutr. Health Aging, 2008, 12(1), 29-37.
37. Martorana, A.; Semprini, R.; Koch, G. Clinical Profile of Alzheimer’s Disease Non-Responder Patient, Advanced Understanding of Neurodegenerative Diseases; Chang, R.C., Ed.; InTech; 2011; ISBN: 978-953-307-529-7.
38. Fagan, A.M.; Mintun, M.A.; Shah, A.R.; Aldea, P.; Roe, C.M.; Mach, R.H.; Marcus, D.; Morris, J.C.; Holtzman, D.M. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol. Med., 2009, 1(8-9), 371-380.
39. Price, J.L.; Morris, J.C. Tangles and plaques in non demented aging and "preclinical" Alzheimer's disease. Ann. Neurol., 1999, 45(3), 358-368.
40. Sunderland, T.; Linker, G.; Mirza, N.; Putnam, K.T.; Friedman, D.L.; Kimmel, L.H.; Bergeson, J.; Manetti, G.J.; Zimmermann, M.; Tang, B.; Bartko, J.J.; Cohen, R.M. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA, 2003, 289(16), 2094-2103.
41. Roberson, E.D.; Halabisky, B.; Yoo, J.W.; Yao, J.; Chin, J.; Yan, F.; Wu, T.; Hamto, P.; Devidze, N.; Yu, G.Q.; Palop, J.J.; Noebels, J.L.; Mucke, L. Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J. Neurosci., 2011, 31(2), 700-711.
42. Ondrejcak, T.; Klyubin, I.; Hu, N.W.; Barry, A.E.; Cullen, W.K.; Rowan, M.J. Alzheimer's disease amyloid beta-protein and synaptic function. Neuromol. Med., 2010, 12, 13-26.
43. Palop, J.J.; Mucke, L. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat. Neurosci., 2010, 13, 812-818.
44. Blennow, K.; Hampel, H. CSF markers for incipient Alzheimer's disease. Lancet Neurol., 2003, 2, 605-613.
45. Ittner, L.M.; Ke, Y.D.; Delerue, F.; Bi, M.; Gladbach, A.; van Eersel, J.; Wölfing, H.; Chieng, B.C.; Christie, M.J.; Napier, I.A.; Eckert, A.; Staufenbiel, M.; Hardeman, E.; Götz, J. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell, 2010, 142(3), 387-397.
46. Amadoro, G.; Corsetti, V.; Stringaro, A.; Colone, M.; D'Aguanno, S.; Meli, G.; Ciotti, M.; Sancesario, G.; Cattaneo, A.; Bussani, R.; Mercanti, D.; Calissano, P. A NH2 tau fragment targets neuronal mitochondria at AD synapses: possible implications for neurodegeneration. J. Alzheimers Dis., 2010, 21(2), 445-470.
47. Jucker, M.; Walker, L.C. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann. Neurol., 2011, 70(4), 532-540.
48. Hall, G.F.; Patuto, B.A. Is tau ready for admission to the prion club? Prion, 2012, 6(3).
49. Iqbal, K.; Flory, M.; Khatoon, S.; Soininen, H.; Pirttila, T.; Lehtovirta, M.; Alafuzoff, I.; Blennow, K.; Andreasen, N.; Vanmechelen, E.; Grundke-Iqbal, I. Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. Ann. Neurol., 2005, 58(5), 748-757.
50. Mattsson, N.; Zetterberg, H.; Hansson, O.; Andreasen, N.; Parnetti, L.; Jonsson, M.; Herukka, S.K.; van der Flier, W.M.; Blankenstein, M.A.; Ewers, M.; Rich, K.; Kaiser, E.; Verbeek, M.; Tsolaki, M.; Mulugeta, E.; Rosén, E.; Aarsland, D.; Visser, P.J.; Schröder, J.; Marcusson, J.; de Leon, M.; Hampel, H.; Scheltens, P.; Pirttilä, T.; Wallin, A.; Jönhagen, M.E.; Minthon, L.; Winblad, B.; Blennow, K. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA, 2009, 302(4), 385-393.
51. Musicco, M.; Salamone, G.; Caltagirone, C.; Cravello, L.; Fadda, L.; Lupo, F.; Mosti, S.; Perri, R.; Palmer, K. Neuropsychological predictors of rapidly progressing patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord., 2010, 30(3), 219-228.